{
  "nctrialId": "HC-1760",
  "title": "A  Double-Blind, Placebo-Controlled  Study of CDN-468 (integrin inhibitor) in Patients With Multiple Sclerosis",
  "officialTitle": "A  Double-Blind, Placebo-Controlled  Study of CDN-468 (integrin inhibitor) in Patients With Multiple Sclerosis",
  "sponsor": "Sunnybrook Research Institute",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 4",
  "fileName": "HC-1760.json",
  "fileSize": 143038,
  "date": "2023-11-02",
  "completionDate": "2027-03-03",
  "drugName": "CDN-468 (integrin inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a  double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of CDN-468 (integrin inhibitor) in patients with Multiple Sclerosis. The study will enroll approximately 267 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-61 years\n- Confirmed diagnosis of Multiple Sclerosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}